Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
Objective. Within the framework of Chronic Myelogenous Leukaemia (CML) treatment in Chile, and based on a previously performed economic evaluation, we compared the costs and cost-effectiveness ratio of using 100 mg/day and 140 mg/day doses of dasatinib with the use of 800 mg/day doses of nilotinib o...
Main Authors: | Milva Caputo, Eleonora Aiello, Juan Esteban Valencia, John Jairo Orozco Giraldo |
---|---|
Format: | Article |
Language: | English |
Published: |
Medwave Estudios Limitada
2011-04-01
|
Series: | Medwave |
Subjects: | |
Online Access: | http://dx.doi.org/10.5867/medwave.2011.04.5012 |
Similar Items
-
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01) -
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
by: Takaaki Ono
Published: (2021-10-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01) -
Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)